A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Myeloid Therapeutics
Seagen Inc.
West China Hospital
Actym Therapeutics, Inc.
Elicio Therapeutics
Jonsson Comprehensive Cancer Center
NextPoint Therapeutics, Inc.
Zymeworks BC Inc.
Symphogen A/S
ABM Therapeutics Shanghai Company Limited
NGM Biopharmaceuticals, Inc
University of California, San Diego
ABM Therapeutics Corporation
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd
Tempest Therapeutics
Xencor, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
Wellmarker Bio
Bayer
AbbVie
AbbVie
Fore Biotherapeutics
AstraZeneca